Clinical research explores the impact of continuous dual glucose-ketone monitoring on type 1 and type 2 diabetes management, suggesting improved patient outcomes.
Severe diabetic ketoacidosis (DKA) is a critical medical condition that often necessitates emergency treatment and hospitalization. Although DKA primarily impacts individuals with type 1 diabetes (T1D), its annual incidence among adults with T1D ranges from 4% to 8% following diagnosis. Continuous glucose monitoring (CGM) has become a standard tool for managing T1D and type 2 diabetes (T2D) in patients using insulin or aiming to improve self-management. However, advances in continuous dual glucose-ketone monitoring (DGK) technology offer new possibilities for clinical research and patient care. This article explores the potential applications of DGK in clinical research, with a focus on T1D, while also considering its broader relevance for T2D and other patient populations.
No takes yet. Share an insight, caveat, or question.
Aktürk et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: